STOCK TITAN
  1. Home
  2. Sec-filings
  3. CHRS
  4. [8-K] Coherus Oncology, Inc. Reports Material Event

CHRS updates 2024–2023 results for discontinued ops tied to UDENYCA sale

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Coherus Oncology (CHRS) recast prior financials to reflect discontinued operations after divesting its UDENYCA franchise. The company completed the UDENYCA sale to Intas on April 11, 2025 for upfront, all‑cash consideration of $483.4 million, which included $118.4 million for product inventory. Coherus is also eligible for two additional earn‑out payments of $37.5 million each.

Exhibit 99.1 updates selected sections of the 2024 Form 10‑K to present the biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations for the fiscal years ended December 31, 2024 and 2023. The recast information is intended for incorporation by reference into a Form S‑3 expected to be filed on November 13, 2025. The filing limits changes to those necessary for the discontinued operations presentation, maintaining the nature and character of the original disclosures.

Positive

  • None.

Negative

  • None.

Insights

Administrative 8-K recast; sale economics already disclosed.

Coherus uses this 8-K to recast historical financials as discontinued operations following the completed sale of the UDENYCA franchise. The economic terms were previously set: upfront all-cash consideration of $483.4 million, including $118.4 million of inventory value, plus eligibility for two earn-outs of $37.5 million each.

The recast moves the biosimilar franchises (UDENYCA, YUSIMRY, CIMERLI) out of continuing operations, clarifying trend lines for the remaining business. The company states the updates are limited to the discontinued operations treatment to preserve the original disclosures.

The company intends to incorporate Exhibit 99.1 into a Form S-3 expected on November 13, 2025. Actual market impact depends on future capital markets actions and subsequent disclosures; this filing itself is largely presentational.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
0001512762false00015127622025-11-132025-11-1300015127622022-01-012022-12-310001512762us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2024-12-310001512762us-gaap:DomesticCountryMemberus-gaap:ResearchMember2024-12-310001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2024-01-012024-12-310001512762us-gaap:AdditionalPaidInCapitalMemberchrs:PublicOfferingMember2023-01-012023-12-310001512762us-gaap:AdditionalPaidInCapitalMemberchrs:OptionalStockPurchaseAgreementMember2023-01-012023-12-310001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2023-01-012023-12-310001512762chrs:OptionalStockPurchaseAgreementMember2023-01-012023-12-310001512762srt:MaximumMemberchrs:AtMarketOfferingMember2022-11-082022-11-080001512762us-gaap:CommonStockMemberchrs:AtMarketOfferingMember2024-01-012024-12-310001512762chrs:ChiefMarketingOfficerMemberchrs:OptionalStockPurchaseAgreementMember2023-10-092023-10-090001512762chrs:PublicOfferingMember2023-05-162023-05-160001512762us-gaap:CommonStockMemberchrs:PublicOfferingMember2023-01-012023-12-310001512762us-gaap:CommonStockMemberchrs:OptionalStockPurchaseAgreementMember2023-01-012023-12-310001512762us-gaap:CommonStockMemberchrs:AtMarketOfferingMember2023-01-012023-12-310001512762us-gaap:RetainedEarningsMember2024-12-310001512762us-gaap:AdditionalPaidInCapitalMember2024-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001512762us-gaap:RetainedEarningsMember2023-12-310001512762us-gaap:AdditionalPaidInCapitalMember2023-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001512762us-gaap:RetainedEarningsMember2022-12-310001512762us-gaap:AdditionalPaidInCapitalMember2022-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001512762chrs:ChiefMarketingOfficerMemberchrs:OptionalStockPurchaseAgreementMember2023-10-090001512762us-gaap:OverAllotmentOptionMember2023-05-160001512762us-gaap:CallOptionMember2020-04-1400015127622020-04-140001512762chrs:ExercisePriceRangeTwoMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeThreeMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeSixMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeOneMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeFourMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeFiveMember2024-01-012024-12-310001512762srt:ChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember2024-01-012024-12-310001512762srt:ChiefExecutiveOfficerMemberchrs:PerformanceBasedVestingOptionsMember2024-01-012024-12-310001512762srt:ChiefExecutiveOfficerMemberchrs:MarketConditionVestingOptionsMember2024-01-012024-12-310001512762chrs:ExercisePriceRangeTwoMember2024-12-310001512762chrs:ExercisePriceRangeThreeMember2024-12-310001512762chrs:ExercisePriceRangeSixMember2024-12-310001512762chrs:ExercisePriceRangeOneMember2024-12-310001512762chrs:ExercisePriceRangeFourMember2024-12-310001512762chrs:ExercisePriceRangeFiveMember2024-12-310001512762us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001512762chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2023-01-012023-12-310001512762us-gaap:RestrictedStockUnitsRSUMember2023-12-310001512762chrs:TwoThousandTenPlanMember2014-01-012023-12-310001512762srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001512762srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001512762us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001512762us-gaap:ProductAndServiceOtherMember2024-01-012024-12-310001512762chrs:ToripalimabMember2024-01-012024-12-310001512762us-gaap:ProductAndServiceOtherMember2023-01-012023-12-310001512762chrs:ToripalimabMember2023-01-012023-12-310001512762us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2023-01-012023-12-310001512762us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2023-01-012023-12-310001512762us-gaap:EmployeeSeveranceMember2023-03-102023-03-100001512762chrs:TermLoansMemberus-gaap:SegmentContinuingOperationsMember2024-05-082024-05-080001512762chrs:TermLoansMemberus-gaap:SegmentDiscontinuedOperationsMember2024-04-012024-04-010001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-04-152025-04-150001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2024-05-082024-05-080001512762us-gaap:SegmentDiscontinuedOperationsMember2024-12-310001512762us-gaap:SegmentContinuingOperationsMember2024-12-310001512762srt:MinimumMemberus-gaap:ComputerEquipmentMember2024-12-310001512762srt:MaximumMemberus-gaap:ComputerEquipmentMember2024-12-3100015127622022-04-012022-04-300001512762chrs:PublicOfferingMember2023-05-182023-05-180001512762chrs:PublicOfferingMember2023-01-012023-12-310001512762chrs:YusimryImmunologyFranchiseMember2024-01-012024-12-310001512762chrs:CimerliOphthalmologyFranchiseMember2024-01-012024-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001512762us-gaap:StateAndLocalJurisdictionMember2024-12-310001512762us-gaap:DomesticCountryMember2024-12-310001512762us-gaap:RetainedEarningsMember2024-01-012024-12-310001512762us-gaap:RetainedEarningsMember2023-01-012023-12-310001512762chrs:AccruedRebatesFeesAndReservesMember2024-12-310001512762chrs:AccruedRebatesFeesAndReservesMember2023-12-310001512762chrs:NewCamarilloLeaseMember2023-01-012023-12-310001512762chrs:CorporateHeadquartersLeaseAgreementMember2023-01-012023-12-310001512762us-gaap:CostOfSalesMemberchrs:UdenycaMember2024-01-012024-12-310001512762chrs:UdenycaMember2024-01-012024-12-310001512762us-gaap:CostOfSalesMemberchrs:YusimryProductMember2023-01-012023-12-310001512762chrs:TermLoansMemberus-gaap:SegmentDiscontinuedOperationsMember2024-01-012024-12-310001512762chrs:TermLoansMemberus-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310001512762chrs:TermLoansMemberus-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-12-310001512762chrs:TermLoansMemberus-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310001512762chrs:OutLicensesWithNovartisInstitutesMember2024-01-012024-03-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-06-262024-06-260001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-04-012025-06-300001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2024-01-012024-12-310001512762us-gaap:LicensingAgreementsMember2024-12-310001512762us-gaap:InProcessResearchAndDevelopmentMember2024-12-310001512762us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:FairValueInputsLevel3Memberchrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762chrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:FairValueInputsLevel3Memberchrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:RestrictedStockUnitsRSUMember2024-12-310001512762chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2024-01-012024-12-310001512762us-gaap:RoyaltyAgreementsMember2024-01-012024-12-310001512762us-gaap:RoyaltyAgreementsMember2024-12-310001512762us-gaap:RoyaltyAgreementsMember2024-05-080001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:UdenycaBusinessMember2024-01-012024-12-310001512762chrs:YusimryImmunologyFranchiseMember2023-01-012023-12-310001512762chrs:UdenycaBusinessMember2023-01-012023-12-310001512762chrs:CimerliOphthalmologyFranchiseMember2023-01-012023-12-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2023-12-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2023-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:YusimryImmunologyFranchiseMember2024-12-310001512762srt:MaximumMemberchrs:Plan401KMember2019-01-012019-12-310001512762srt:MaximumMemberchrs:Plan401KMember2024-01-012024-12-310001512762chrs:Plan401KMember2024-01-012024-12-310001512762chrs:Plan401KMember2023-01-012023-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-05-150001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-04-150001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-05-152025-05-150001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-12-3100015127622024-10-012024-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2025-06-300001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:FairValueInputsLevel2Member2024-12-310001512762chrs:TermLoansMemberus-gaap:SegmentDiscontinuedOperationsMember2024-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:FairValueInputsLevel2Member2024-12-310001512762chrs:TermLoansMember2024-12-310001512762chrs:AnkuraTrustCompanyLlcMemberchrs:TwoThousandTwentyNineTermLoansMember2024-05-080001512762chrs:TermLoansMember2024-04-010001512762chrs:TermLoansMemberus-gaap:FairValueInputsLevel2Member2023-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:FairValueInputsLevel2Member2023-12-310001512762us-gaap:ScenarioPlanMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-01-012024-12-310001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001512762us-gaap:CommonStockMember2024-12-310001512762us-gaap:CommonStockMember2023-12-310001512762us-gaap:CommonStockMember2022-12-310001512762chrs:PublicOfferingMember2023-05-160001512762chrs:TwoThousandTenPlanMember2024-12-310001512762chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember2024-12-310001512762chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2024-12-310001512762chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember2024-05-290001512762chrs:SurfaceOncologyInc.Memberus-gaap:LicensingAgreementsMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberus-gaap:InProcessResearchAndDevelopmentMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithGrkMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:InProcessResearchAndDevelopmentSrf388Member2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:InProcessResearchAndDevelopmentChs114Member2023-09-0800015127622025-04-300001512762chrs:SurfaceOncologyInc.Member2024-12-310001512762chrs:SurfaceOncologyInc.Member2024-03-310001512762chrs:SurfaceOncologyInc.Member2024-01-012024-03-310001512762chrs:SurfaceOncologyInc.Member2023-01-012023-12-310001512762us-gaap:MoneyMarketFundsMember2024-12-310001512762us-gaap:MoneyMarketFundsMember2023-12-310001512762us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762us-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001512762us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:PrepaidExpensesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:PrepaidExpensesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:LaboratoryFacilitiesLeaseAgreementMember2023-12-310001512762chrs:CorporateHeadquartersLeaseAgreementMember2023-12-310001512762chrs:OfficeSpaceRemainingPremisesMemberchrs:SixthAmendmentToLeaseMember2023-10-240001512762chrs:SixthAmendmentToLeaseMember2023-10-240001512762chrs:ConvertibleNotesMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-01-012024-12-310001512762us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001512762chrs:EmployeesAndNonemployeesStockOptionMember2024-01-012024-12-310001512762chrs:ConvertibleNotesMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2023-01-012023-12-310001512762us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001512762chrs:EmployeesAndNonemployeesStockOptionMember2023-01-012023-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-01-012024-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2023-01-012023-12-310001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310001512762us-gaap:SegmentDiscontinuedOperationsMember2024-01-012024-12-310001512762us-gaap:SegmentContinuingOperationsMember2024-01-012024-12-310001512762us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310001512762us-gaap:CostOfSalesMember2024-01-012024-12-310001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001512762us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-12-310001512762us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310001512762us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithGrkMember2023-09-082023-09-080001512762chrs:JunshiBiosciencesMember2024-12-310001512762srt:WeightedAverageMemberchrs:AtMarketOfferingMember2024-01-012024-12-310001512762srt:WeightedAverageMemberchrs:AtMarketOfferingMember2023-01-012023-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:CimerliOphthalmologyFranchiseMember2024-12-310001512762chrs:ScenarioNetSalesExceeding350MillionQuartersEndingMarch312027Memberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:UdenycaBusinessMember2025-04-112025-04-110001512762chrs:ScenarioNetSalesExceeding300MillionQuartersEndingSeptember302026Memberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:UdenycaBusinessMember2025-04-112025-04-110001512762us-gaap:DomesticCountryMemberus-gaap:ResearchMember2024-01-012024-12-310001512762us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001512762us-gaap:CommonStockMember2023-01-012023-12-310001512762us-gaap:CommonStockMember2024-01-012024-12-310001512762us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001512762chrs:YusimryProductMember2023-01-012023-12-310001512762us-gaap:OverAllotmentOptionMember2023-05-162023-05-160001512762chrs:AtMarketOfferingMember2023-05-150001512762srt:MaximumMemberchrs:AtMarketOfferingMember2023-09-110001512762srt:MaximumMemberchrs:PublicOfferingMember2023-05-160001512762srt:MaximumMemberchrs:AtMarketOfferingMember2023-05-150001512762srt:MaximumMemberchrs:AtMarketOfferingMember2022-11-080001512762us-gaap:EmployeeSeveranceMember2023-01-012023-03-310001512762us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001512762us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-01-012024-12-310001512762chrs:TermLoansMember2024-01-012024-12-310001512762chrs:RevenuePurchaseAndSaleAgreementMember2025-01-012025-03-310001512762chrs:UdenycaMemberchrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:UdenycaAndLoqtorziMemberchrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:RebatesMember2024-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2024-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2024-12-310001512762chrs:RebatesMember2023-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2023-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2023-12-310001512762chrs:RebatesMember2022-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2022-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2022-12-3100015127622022-12-310001512762srt:MinimumMemberchrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2014-10-312014-10-310001512762chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember2024-01-012024-12-310001512762us-gaap:MachineryAndEquipmentMember2024-12-310001512762us-gaap:LeaseholdImprovementsMember2024-12-310001512762us-gaap:FurnitureAndFixturesMember2024-12-310001512762us-gaap:ComputerEquipmentMember2024-12-310001512762us-gaap:MachineryAndEquipmentMember2023-12-310001512762us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-12-310001512762us-gaap:LeaseholdImprovementsMember2023-12-310001512762us-gaap:FurnitureAndFixturesMember2023-12-310001512762us-gaap:ComputerEquipmentMember2023-12-310001512762chrs:AtMarketOfferingMember2024-01-012024-12-310001512762chrs:AtMarketOfferingMember2023-01-012023-12-310001512762chrs:LoqtorziMember2024-12-310001512762chrs:LoqtorziMember2019-05-020001512762chrs:BioeqIPAGMember2019-11-042019-11-040001512762srt:MinimumMember2024-01-012024-12-310001512762srt:MaximumMember2024-01-012024-12-310001512762chrs:RevenuePurchaseAndSaleAgreementMemberchrs:UdenycaBusinessMember2025-04-152025-04-150001512762chrs:RebatesMember2024-01-012024-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2024-01-012024-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2024-01-012024-12-310001512762chrs:RebatesMember2023-01-012023-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2023-01-012023-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2023-01-012023-12-310001512762us-gaap:StateAndLocalJurisdictionMember2024-01-012024-12-310001512762us-gaap:DomesticCountryMember2024-01-012024-12-310001512762chrs:VehiclesLeaseMember2019-01-012019-12-310001512762chrs:ChiefMarketingOfficerMemberchrs:OptionalStockPurchaseAgreementMember2023-10-042023-10-040001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:UdenycaBusinessMember2025-04-1100015127622024-02-052024-02-050001512762chrs:ToripalimabMemberchrs:JunshiBiosciencesMember2024-01-012024-12-3100015127622024-03-012024-03-310001512762us-gaap:LicenseMemberchrs:JunshiBiosciencesMember2021-02-012021-02-010001512762chrs:TwoThousandTwentyNineTermLoansMember2024-12-310001512762us-gaap:CostOfSalesMember2023-01-012023-12-310001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-05-082024-05-080001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-05-082024-05-080001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-05-082024-05-080001512762chrs:RevenuePurchaseAndSaleAgreementMemberchrs:UdenycaBusinessMemberus-gaap:InterestExpenseMember2024-01-012024-12-310001512762chrs:RevenuePurchaseAndSaleAgreementMemberus-gaap:InterestExpenseMember2024-01-012024-12-310001512762chrs:AtMarketOfferingMember2023-09-112023-09-110001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2024-01-012024-03-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-03-012024-03-010001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2020-04-012020-04-300001512762chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2014-10-312014-10-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:UdenycaBusinessMember2025-04-112025-04-110001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:YusimryImmunologyFranchiseMember2024-01-012024-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:CimerliOphthalmologyFranchiseMember2024-01-012024-12-310001512762us-gaap:DiscontinuedOperationsHeldforsaleMember2024-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-12-310001512762us-gaap:DiscontinuedOperationsHeldforsaleMember2023-12-310001512762us-gaap:DiscontinuedOperationsHeldforsaleMemberchrs:YusimryImmunologyFranchiseAndCimerliOphthalmologyFranchiseMember2023-01-012023-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:YusimryImmunologyFranchiseMember2024-06-260001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:YusimryImmunologyFranchiseAndCimerliOphthalmologyFranchiseMember2024-01-012024-12-310001512762us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:CimerliOphthalmologyFranchiseMember2024-03-010001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-12-310001512762chrs:ScenarioNetSalesExceeding350MillionQuartersEndingMarch312027Memberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:UdenycaBusinessMember2025-04-110001512762chrs:ScenarioNetSalesExceeding300MillionQuartersEndingSeptember302026Memberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberchrs:UdenycaBusinessMember2025-04-110001512762chrs:JunshiBiosciencesMember2024-01-012024-12-3100015127622024-02-050001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2024-05-080001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2022-01-050001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2020-04-300001512762chrs:TwoThousandTwentyNineTermLoansMember2024-01-012024-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-01-012024-12-310001512762chrs:TwoThousandTwentyNineTermLoansMember2024-05-082024-05-080001512762chrs:TermLoansMember2024-04-012024-04-010001512762chrs:AtMarketOfferingMember2024-12-310001512762chrs:ToripalimabMemberchrs:JunshiBiosciencesMember2021-02-012021-02-010001512762chrs:Chs006AntiTigitAntibodyMember2021-02-010001512762chrs:CanadaLicenseAgreementMember2024-01-012024-12-310001512762chrs:Chs006AntiTigitAntibodyMember2022-03-012022-03-310001512762chrs:Chs006AntiTigitAntibodyMember2021-02-012021-02-010001512762chrs:JunshiBiosciencesMember2021-02-012021-02-010001512762chrs:SurfaceMemberchrs:GskAgreementMember2022-03-012022-03-310001512762chrs:AntiTigitAntibodyAndIl2CytokineMemberchrs:Chs006AntiTigitAntibodyMember2022-03-310001512762chrs:ToripalimabMemberchrs:JunshiBiosciencesMember2024-12-310001512762chrs:VaccinexLicenseAgreementMember2021-03-232021-03-230001512762chrs:AdimabDevelopmentAndOptionAgreementMember2018-10-012018-10-310001512762chrs:GskAgreementMember2020-12-012020-12-310001512762us-gaap:AccountsPayableMemberchrs:JunshiBiosciencesMember2024-12-310001512762chrs:AccruedAndOtherCurrentLiabilitiesMemberchrs:JunshiBiosciencesMember2024-12-310001512762us-gaap:AccountsPayableMemberchrs:JunshiBiosciencesMember2023-12-310001512762chrs:AccruedAndOtherCurrentLiabilitiesMemberchrs:JunshiBiosciencesMember2023-12-310001512762us-gaap:CallOptionMember2020-04-012020-04-3000015127622023-01-012023-12-310001512762chrs:SurfaceOncologyInc.Member2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceSrf388ProprietaryDrugProductAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceSrf114ProprietaryDrugProductAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceGlaxosmithklineAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Member2023-09-082023-09-080001512762us-gaap:LicenseMemberchrs:BioeqIPAGMember2022-01-012022-12-3100015127622024-01-012024-12-310001512762chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMemberchrs:JunshiBiosciencesMember2024-03-310001512762chrs:JunshiBiosciencesMember2023-10-2700015127622024-12-3100015127622023-12-310001512762chrs:DiscontinuedOperationsClassifiedAsNotHeldForSaleMember2024-12-310001512762chrs:DiscontinuedOperationsClassifiedAsNotHeldForSaleMember2023-12-31chrs:positionchrs:employeeiso4217:USDiso4217:EURxbrli:purechrs:itemxbrli:sharesiso4217:USDxbrli:shareschrs:paymentchrs:segmentutr:sqft

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

​

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 13, 2025

​

​

COHERUS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

​

​

Delaware

 

001-36721

 

27-3615821

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

​

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

​

Registrant’s telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

    

Trading
Symbol(s)

    

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share

 

CHRS

 

The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

​

​

Item 8.01   Other Events.

Coherus Oncology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2025 (the “2024 Form 10-K”) to provide retrospective discontinued operations presentation for the years ended December 31, 2024 and 2023 reflected in the 2024 Form 10-K. The recast financial information is attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to incorporate by reference into a registration statement on Form S-3 expected to be filed by the Company on November 13, 2025.

On December 2, 2024, the Company and Intas Pharmaceuticals Ltd. (“Intas”) entered into an asset purchase agreement (the “UDENYCA Purchase Agreement”), pursuant to which, and upon the terms and subject to the conditions thereof, the Company agreed to divest the UDENYCA franchise (the “UDENYCA Business”) to Intas (the “UDENYCA Sale”). On April 11, 2025, the Company completed the divestiture of the UDENYCA Business to Intas for upfront, all-cash consideration of $483.4 million, inclusive of $118.4 million for UDENYCA product inventory. In addition, the Company is also eligible to receive two additional earn-out payments of $37.5 million each.

The UDENYCA Sale represented the last and most significant divestiture of the Company’s biosimilar businesses, which comprised the UDENYCA, YUSIMRY and CIMERLI franchises; representing a strategic shift resulting in a major effect on the Company’s business and therefore met the criteria for classification as discontinued operations. Accordingly, starting with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, the Company began to classify its condensed consolidated financial statements as discontinued operations for all periods presented. The Company’s consolidated financial statements, recast to reflect the retrospective presentation of discontinued operations for the fiscal years ended December 31, 2024 and 2023, are presented within Exhibit 99.1 to this Current Report on Form 8-K

In order to preserve the nature and character of the disclosures set forth in the 2024 Form 10-K, the items included in Exhibit 99.1 to this Form 8-K have been updated solely for matters relating specifically to the treatment of the Company’s biosimilar businesses as discontinued operations. This Form 8-K does not reflect other events occurring after the filing date of the 2024 Form 10-K, except as otherwise reflected in Exhibit 99.1. Unless otherwise noted, applicable amounts in the comparative periods have been recast to conform to this discontinued operations presentation. This Form 8-K should be read in conjunction with the 2024 Form 10-K and the filings with the SEC made by the Company after the filing of the 2024 Form 10-K, including the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, and the other filings with the SEC made by the Company after the filing of the 2024 Form 10-K.

The following items of the 2024 Form 10-K have been recast to reflect the retrospective presentation of discontinued operations as shown in Exhibit 99.1 to this Form 8-K:

●Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
●Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” and
●Part II, Item 8. “Financial Statements and Supplementary Data”

​

​

​

Item 9.01   Financial Statements and Exhibits.

(d)         Exhibits.

​

​

​

​

Exhibit No.

    

Description

​

​

​

23.1

​

Consent of Independent Registered Public Accounting Firm

​

​

​

99.1

​

Updated Part II, Items 7. and 7A. “Management’s Discussion and Analysis of Financial Condition and Results of Operations and Quantitative and Qualitative Disclosures About Market Risk,” and Part II, Item 8. “Financial Statements and Supplementary Data” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024

​

101.INS

​

​

101.SCH

​

101.CAL

​

101.DEF

​

101.LAB

​

101.PRE

​

​

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

​

Inline XBRL Taxonomy Extension Schema Document

​

Inline XBRL Taxonomy Extension Calculation Linkbase Document

​

Inline XBRL Taxonomy Extension Definition Linkbase Document

​

Inline XBRL Taxonomy Extension Label Linkbase Document

​

Inline XBRL Taxonomy Extension Presentation Linkbase Document

​

104

​

Cover page Interactive Data file (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

Date: November 13, 2025

    

COHERUS ONCOLOGY, INC.

​

​

​

​

​

​

By:

/s/ Dennis M. Lanfear

​

​

Name:

Dennis M. Lanfear

​

​

Title:

Chief Executive Officer

​

​

​

​

Source: View Original Filing on SEC EDGAR

FAQ

What did Coherus Oncology (CHRS) announce in this 8-K?

Coherus filed recast financial information to present its biosimilar businesses as discontinued operations, attached as Exhibit 99.1.

What were the terms of the UDENYCA sale mentioned by CHRS?

Coherus completed the sale for upfront, all-cash consideration of $483.4 million, including $118.4 million for inventory, plus eligibility for two $37.5 million earn-outs.

Which periods were recast as discontinued operations by CHRS?

The fiscal years ended December 31, 2024 and December 31, 2023 were recast.

Which businesses are classified as discontinued operations?

The biosimilar franchises: UDENYCA, YUSIMRY, and CIMERLI.

When did the UDENYCA sale to Intas close?

The transaction closed on April 11, 2025.

How will the recast information be used by CHRS?

Exhibit 99.1 is intended to be incorporated by reference into a Form S‑3 expected to be filed on November 13, 2025.